DK1039882T3 - Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse - Google Patents

Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse

Info

Publication number
DK1039882T3
DK1039882T3 DK99946521.4T DK99946521T DK1039882T3 DK 1039882 T3 DK1039882 T3 DK 1039882T3 DK 99946521 T DK99946521 T DK 99946521T DK 1039882 T3 DK1039882 T3 DK 1039882T3
Authority
DK
Denmark
Prior art keywords
administration
controlled release
therapeutic formulation
release tolterodine
tolterodine
Prior art date
Application number
DK99946521.4T
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Birgitta Olsson
Ulla Hoeck
Torkel Gren
Anders Ringberg
Martin Wikberg
Bengt Hallen
Jan Stroembom
Bo Kreilgaard
Jacobsen Lene Orup
Helle Kristensen
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1039882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of DK1039882T3 publication Critical patent/DK1039882T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK99946521.4T 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse DK1039882T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number Publication Date
DK1039882T3 true DK1039882T3 (da) 2011-01-24

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99946521.4T DK1039882T3 (da) 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse

Country Status (30)

Country Link
US (1) US6770295B1 (da)
EP (2) EP2153825A1 (da)
CN (1) CN1239152C (da)
AP (1) AP1529A (da)
AR (1) AR029311A1 (da)
AT (1) ATE487471T1 (da)
AU (1) AU745190B2 (da)
BG (1) BG65168B1 (da)
CA (1) CA2311755C (da)
CY (1) CY1111088T1 (da)
CZ (1) CZ302630B6 (da)
DE (1) DE69942928D1 (da)
DK (1) DK1039882T3 (da)
EA (1) EA002720B1 (da)
GE (1) GEP20043354B (da)
HU (1) HUP0100437A3 (da)
ID (1) ID25824A (da)
IL (1) IL136294A (da)
IS (1) IS2976B (da)
ME (1) ME00850B (da)
MY (1) MY127946A (da)
NO (1) NO329830B1 (da)
NZ (1) NZ504618A (da)
OA (1) OA11636A (da)
PT (1) PT1039882E (da)
SI (1) SI1039882T1 (da)
SK (1) SK287111B6 (da)
TR (1) TR200001998T1 (da)
UA (1) UA72882C2 (da)
WO (1) WO2000012069A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
ATE432070T1 (de) * 2003-01-22 2009-06-15 Pfizer Health Ab Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
DK2210605T3 (da) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daglige engangsdosisformer af trospium.
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2301086C2 (ru) * 2004-12-27 2007-06-20 Государственное образовательное учреждение высшего профессионального образования Алтайский государственный медицинский университет Минздрава России (ГОУ ВПО АГМУ МЗ РФ) Способ лечения гиперактивного мочевого пузыря
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
KR101685031B1 (ko) 2008-04-02 2016-12-09 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
RU2396920C1 (ru) * 2008-12-29 2010-08-20 Николай Владимирович Карюкин Способ лечения гиперактивного мочевого пузыря
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20130195957A1 (en) * 2010-08-03 2013-08-01 Hisamitsu Pharmaceutical Co., Inc. Patch and method for enhancing adhesion force of the same
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP4596045A3 (en) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
JP3786684B2 (ja) * 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1996012477A1 (en) * 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
CA2259012C (en) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법

Also Published As

Publication number Publication date
AP1529A (en) 2006-01-03
AP2000001823A0 (en) 2000-06-30
AR029311A1 (es) 2003-06-25
ME00850B (me) 2008-08-07
EA002720B1 (ru) 2002-08-29
HK1034664A1 (en) 2001-11-02
CA2311755C (en) 2010-03-23
US6770295B1 (en) 2004-08-03
ID25824A (id) 2000-11-09
TR200001998T1 (tr) 2001-01-22
HUP0100437A2 (hu) 2002-05-29
IS5537A (is) 2000-06-15
EA200000468A1 (ru) 2000-12-25
PT1039882E (pt) 2011-01-03
BG104476A (en) 2000-12-29
CN1287484A (zh) 2001-03-14
SK7492000A3 (en) 2001-02-12
NO20002977D0 (no) 2000-06-09
DE69942928D1 (de) 2010-12-23
UA72882C2 (uk) 2005-05-16
CN1239152C (zh) 2006-02-01
SK287111B6 (sk) 2009-12-07
CA2311755A1 (en) 2000-03-09
OA11636A (en) 2004-09-03
CZ20001924A3 (cs) 2001-04-11
SI1039882T1 (sl) 2011-01-31
ATE487471T1 (de) 2010-11-15
EP1039882B1 (en) 2010-11-10
NO20002977L (no) 2000-06-09
IL136294A0 (en) 2001-05-20
GEP20043354B (en) 2004-04-13
IS2976B (is) 2017-07-15
BG65168B1 (bg) 2007-05-31
EP1039882A1 (en) 2000-10-04
AU5891899A (en) 2000-03-21
IL136294A (en) 2004-02-08
NO329830B1 (no) 2011-01-03
CZ302630B6 (cs) 2011-08-10
HUP0100437A3 (en) 2002-08-28
MY127946A (en) 2007-01-31
EP2153825A1 (en) 2010-02-17
AU745190B2 (en) 2002-03-14
CY1111088T1 (el) 2015-06-11
NZ504618A (en) 2002-09-27
WO2000012069A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
NO20002977L (no) Terapeutisk formulering for administrasjon av tolterodin med kontrollert frigivelse
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
NO995753D0 (no) Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament
DK0758244T3 (da) Doseringsformer af azithromycin med styret frigivelse
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1140105T3 (da) Galantaminpræparat med styret frigivelse
DK1140034T3 (da) Formulering af divalproex-natrium med kontrolleret frigivelse
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
DK200200116U4 (da) Mundhygiejnepræparat til behandling af halitosis
DK0746310T3 (da) Præparat med styret afgivelse
DK1083902T3 (da) Nye galeniske præparatformer af meloxicam til oral administrering
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
DK1171053T3 (da) Apparat til behandling af tandkaries
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
PT868911E (pt) Formulacoes de rapamicina para administracao oral
DK1007024T3 (da) Doseringsformer af sertralin med forsinket frigivelse
NO20014049L (no) Kontrollert frigjörings-formulering for behandling av COPD
EE200100453A (et) Betahistiini reguleeritult vabastav preparaat
IS6172A (is) Notkun melatoníns til lækninga
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
DK1591122T3 (da) Fremgangsmåde til indgivelse af bisphosphonater
DK1345605T3 (da) Varmformet lægemiddelsammensætning til styret afgivelse af perindopril